Results 181 to 190 of about 516,619 (288)

Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings. [PDF]

Adv Hematol
Gonugunta AS, Haider A, Mohlere V, Aljurf M, Hashmi S, Abid MB.   +5 more
europepmc   +1 more source

Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Haemophilia, EarlyView.
ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D'Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro   +8 more
wiley   +1 more source

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia. [PDF]

Blood Adv
Gaballa MR, Julian K, Afrough A, Hansen DK, Goel U, De Menezes Silva Corraes A, Dima D, Rana M, Hosoya H, Mikkilineni L, Fogel L, Raza S, Banerjee R, Zanwar SS, Pasvolsky O, Sannareddy A, Borogovac A, Davis J, Green K, Biran N, Zolotov E, Herr M, Shune L, Ouchveridze E, DeJarnette S, Atrash S, Ferreri C, Richards T, Abid MB, Bal S, Ali HM, Ye JC, Richard S, Kaur G, Shain K, Castaneda-Puglianini O, Harada K, De Avila G, Rossi A, Hassan H, Anderson LD, Voorhees PM, Khouri J, Sidana S, Portuguese AJ, Janakiram M, Lee HC, Lin Y, Grajales-Cruz A, Patel KK, Sborov DW.   +50 more
europepmc   +1 more source

Patient Perspectives in Haemophilia A: Unmet Needs of Individuals Receiving Factor and Non‐Factor Treatments

Haemophilia, EarlyView.
ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh, Veruska Carboni, Duygu Bozkaya, Idaira Rodriguez‐Santana, Claudia Mighiu, Bethany Franks, Arnoud Plat, Randall Curtis   +7 more
wiley   +1 more source

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma. [PDF]

Cancer
Worth HA, Costa LJ.
europepmc   +1 more source

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

Histopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek   +7 more
wiley   +1 more source

Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation. [PDF]

Antibodies (Basel)
Bruzzese A, Martino EA, Caserta S, Alvaro ME, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Vigna E, Gentile M.   +11 more
europepmc   +1 more source

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma. [PDF]

Cancers (Basel)
Martino M, Marafioti V, Pitea M, Porto G, Policastro G, Canale FA, Naso V, Alati C.   +7 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

Immunology, EarlyView.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia, Emily Pauline Nickles, Yu Mei, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu, Rui Sun, Kang Yi Lee, Gloryn Chia, Chwee Ming Lim, Herbert Schwarz   +10 more
wiley   +1 more source

DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. [PDF]

Cancer Immunol Res
Aleynick M, Wang Q, Wu JE, Lemus S, Chaimowitz M, Mir H, Warsaw JJ, Guo C, Macdonald LE, Waite JC, Kourtis N, Skokos D.   +11 more
europepmc   +1 more source